Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Listening...

Search Results

No Results

    See all results

    Sorry, I don't understand. Please try again
    1. Home/
    2. Media Center/
    3. Press releases /
    4. Innovative Medicine

    Innovative Medicine

    Innovative Medicine
    May 31, 2012

    Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes

    Learn more
    Innovative Medicine
    May 29, 2012

    FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet

    Learn more
    Innovative Medicine
    May 23, 2012

    FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

    Learn more
    Innovative Medicine
    May 23, 2012

    Janssen Healthcare Innovation Announces Discharge Decision Support System (D2S2) Winner of the Janssen Connected Care Challenge

    $100,000 award to advance commercialization of D2S2 transition care solution designed to deliver better patient care and reduce hospital readmissions
    Learn more
    Innovative Medicine
    May 21, 2012

    New Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in Adults with Moderately To Severely Active Ulcerative Colitis

    First Presentation of Phase 3 Data Shows Significant Improvements in Clinical Remission, Mucosal Healing and Quality of Life Measures after SIMPONI Induction Treatment
    Learn more
    Innovative Medicine
    May 18, 2012

    ZYTIGA® (abiraterone acetate) Data to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting

    Note: This release corresponds to ASCO abstracts LBA 4518, 4521, 4556 and 4558
    Learn more
    Innovative Medicine
    May 17, 2012

    Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)

    Study results presented at the 31st Annual Scientific Meeting of the American Pain Society
    Learn more
    Innovative Medicine
    May 9, 2012

    Janssen Research & Development Submits Supplemental New Drug Application To U.S. FDA For XARELTO® (rivaroxaban) To Reduce The Risk Of Stent Thrombosis In Patients With Acute Coronary Syndrome

    Learn more
    Innovative Medicine
    May 2, 2012

    Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism

    Learn more
    Load more